Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Heat Shock Factor 1 Promotes NF-Kb and B-Cell Signaling in a Preclinical Model of Chronic Lymphocytic Leukemia

Rekha Rao, PhD, Trisha Home, M.S, Abdulraheem Yacoub, MD, Huidong Shi, PhD, Ashok Saluja, PhD, Joseph McGuirk, DO, Siddhartha Ganguly, MD

Blood (2015) 126 (23): 5297.

https://doi.org/10.1182/blood.V126.23.5297.5297

Published: 2015

Journal Articles

Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells

Rekha Rao, PhD, Kami Maddocks, MD, Amy J. Johnson, PhD, Lata Chauhan, PhD, Suman Kambhampati, MD, Siddhartha Ganguly, MD, Ruben Reyes, MD, Omar S. Aljitawi, MD, Kevin Schorno, MBA, Kendra Ford, MSN, RN, CCRC, Eileen Dickman, PhD, MBA, John C. Byrd, MD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 929.

https://doi.org/10.1182/blood.V118.21.929.929

Published: 2011

Journal Articles

Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists

Ramesh Balusu, PhD, Josiah Cox, Stacey Hembruff, MS, Warren Fiskus, BSc, PhD, Rekha Rao, PhD, Uma Mudunuru, MS, Ruben Reyes, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Heather Male, MD, Allan Fleming, MD, Casey B Williams, Pharm.D., Joseph McGuirk, DO, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 733.

https://doi.org/10.1182/blood.V118.21.733.733

Published: 2011

Journal Articles

Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells

Warren Fiskus, PhD, Sunil Sharma, MD, Rekha Rao, PhD, Ramesh Balusu, PhD, Sreedhar Venkannagari, PhD, Stacey Hembruff, MS, Siddhartha Ganguly, MD, Eduardo M. Sotomayor, Jianguo Tao, MD, PhD, David J. Bearss, PhD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 2429.

https://doi.org/10.1182/blood.V118.21.2429.2429

Published: 2011

Journal Articles

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

Ramesh Balusu, Warren Fiskus, Rekha Rao, Daniel G. Chong, Srilatha Nalluri, Uma Mudunuru, Hongwei Ma, Lei Chen, Sreedhar Venkannagari, Kyungsoo Ha, Sunil Abhyankar, Casey Williams, Joseph McGuirk, Hanna Jean Khoury, Celalettin Ustun, Kapil N. Bhalla

Blood (2011) 118 (11): 3096–3106.

https://doi.org/10.1182/blood-2010-09-309674

Published: 2011

Includes: Supplemental data

Journal Articles

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Aditya Mandawat, Warren Fiskus, Kathleen M. Buckley, Kelly Robbins, Rekha Rao, Ramesh Balusu, Jean-Marc Navenot, Zi-Xuan Wang, Celalettin Ustun, Daniel G. Chong, Peter Atadja, Nobutaka Fujii, Stephen C. Peiper, Kapil Bhalla

Blood (2010) 116 (24): 5306–5315.

https://doi.org/10.1182/blood-2010-05-284414

Published: 2010

Journal Articles

Efficacy of Combined Epigenetic Targeting of Histone Methyltransferase EZH2 and Histone deacetylases Against Human Mantle Cell Lymphoma Cells

Warren Fiskus, BSc, PhD, Rekha Rao, Ramesh Balusu, Jianguo Tao, MD, PhD, Eduardo M. Sotomayor, MD, Peter Atadja, Kapil N. Bhalla, MD

Blood (2010) 116 (21): 2488.

https://doi.org/10.1182/blood.V116.21.2488.2488

Published: 2010

Journal Articles

Synergistic Activity of Combinations of JAK2 Kinase Inhibitor with PI3K/mTOR, MEK or PIM Kinase Inhibitor Against Human Myeloproliferative Neoplasm Cells Expressing JAK2V617F

Warren Fiskus, BSc, PhD, Rekha Rao Manepalli, Ramesh Balusu, Kapil N. Bhalla, MD

Blood (2010) 116 (21): 798.

https://doi.org/10.1182/blood.V116.21.798.798

Published: 2010

Journal Articles

Treatment with Histone Deacetylase 6-Specific Inhibitor WT-161 Disrupts hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal ER Stress Induced by Proteasome Inhibitor Carfilzomib

Rekha Rao, Warren Fiskus, BSc, PhD, Ramesh Balusu, Hongwei Ma, James Bradner, M.D., Jianguo Tao, MD, PhD, Eduardo M. Sotomayor, MD, Kapil N. Bhalla, MD

Blood (2010) 116 (21): 2856.

https://doi.org/10.1182/blood.V116.21.2856.2856

Published: 2010

Journal Articles

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

Yongchao Wang, Warren Fiskus, Daniel G. Chong, Kathleen M. Buckley, Kavita Natarajan, Rekha Rao, Atul Joshi, Ramesh Balusu, Sanjay Koul, Jianguang Chen, Andrew Savoie, Celalettin Ustun, Anand P. Jillella, Peter Atadja, Ross L. Levine, Kapil N. Bhalla

Blood (2009) 114 (24): 5024–5033.

https://doi.org/10.1182/blood-2009-05-222133

Published: 2009

Includes: Supplemental data

Journal Articles

Synergistic Activity of Co-Treatment with PIM1 Kinase Inhibitor SGI-1776 and Histone Deacetylase Inhibitor Panobinostat or Heat Shock Protein 90 Inhibitor AUY922 against Human CML and Myeloproliferative Neoplasm (MPN) Cells.

Warren C. Fiskus, Kathleen M. Buckley, Rekha Rao, Yongchao Wang, Atul Joshi, Daniel G. Chong, Anand Jillella, Celalettin Ustun, Peter Atajada, Cornelia Quadt, Kapil N. Bhalla

Blood (2009) 114 (22): 2651.

https://doi.org/10.1182/blood.V114.22.2651.2651

Published: 2009

Journal Articles

Targeting Levels, Aberrant Localization or Oligomerization of Mutant Nucleophosmin Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1.

Ramesh Balusu, Warren C. Fiskus, Rekha Rao, Kathleen M. Buckley, Yongchao Wang, Atul Joshi, Sanjay Koul, Anand Jillella, Celalettin Ustun, Susan Sunay, H. Jean Khoury, Kapil N. Bhalla

Blood (2009) 114 (22): 2656.

https://doi.org/10.1182/blood.V114.22.2656.2656

Published: 2009

Journal Articles

Down-Regulation of Microrna 223 and 148a Mediates Resistance of Human Acute Myeloid Leukemia Cells to Pan-Histone Deacetylase (HDAC) Inhibitors.

Jianguang Chen, Veena Kandaswamy, Warren Fiskus, Yongchao Wang, Rekha Rao, Ramesh Balusu, Kathleen M. Buckley, Peter Atajada, Kapil N. Bhalla

Blood (2009) 114 (22): 2401.

https://doi.org/10.1182/blood.V114.22.2401.2401

Published: 2009

Journal Articles

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

Warren Fiskus, Yongchao Wang, Arun Sreekumar, Kathleen M. Buckley, Huidong Shi, Anand Jillella, Celalettin Ustun, Rekha Rao, Pravina Fernandez, Jianguang Chen, Ramesh Balusu, Sanjay Koul, Peter Atadja, Victor E. Marquez, Kapil N. Bhalla

Blood (2009) 114 (13): 2733–2743.

https://doi.org/10.1182/blood-2009-03-213496

Published: 2009

Includes: Supplemental data

Journal Articles

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77–based mechanism

Jianguang Chen, Warren Fiskus, Kelly Eaton, Pravina Fernandez, Yongchao Wang, Rekha Rao, Pearl Lee, Rajeshree Joshi, Yonghua Yang, Ravindra Kolhe, Ramesh Balusu, Prasanthi Chappa, Kavita Natarajan, Anand Jillella, Peter Atadja, Kapil N. Bhalla

Blood (2009) 113 (17): 4038–4048.

https://doi.org/10.1182/blood-2008-08-176024

Published: 2009

Includes: Supplemental data

Journal Articles

Combined Epigenetic Therapy with the Novel Histone Methyl Transferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat Exerts Synergistic Activity against Human Mantle Cell Lymphoma Cells

Warren Fiskus, Yongchao Wang, Anand Jillella, Pace Johnston, Rajeshree Joshi, Rekha Rao, Eduardo Sotomayor, Jianguo Tao, Peter Atadja, Victor Marqez, Kapil N. Bhalla

Blood (2008) 112 (11): 3622.

https://doi.org/10.1182/blood.V112.11.3622.3622

Published: 2008

Journal Articles

Anti-AML Activity of Combined Epigenetic Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036 and Histone Deacetylase Inhibitor Panobinostat.

Warren Fiskus, Pace Johnston, Rajeshree Joshi, Rekha Rao, Celalettin Ustun, Anand Jillella, Peter Atadja, Stuart Hwang, Sanjeev Redkar, Kapil N. Bhalla

Blood (2008) 112 (11): 3355.

https://doi.org/10.1182/blood.V112.11.3355.3355

Published: 2008

Journal Articles

Synergistic Pre-Clinical Activity of Combined Epigenetic Therapy with the Novel Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat against Human AML Cells.

Warren Fiskus, Yongchao Wang, Anand Jillella, Celalettin Ustun, Pace Johnston, Rajeshree Joshi, Rekha Rao, Peter Ataja, Victor Marquez, Kapil N. Bhalla

Blood (2008) 112 (11): 3356.

https://doi.org/10.1182/blood.V112.11.3356.3356

Published: 2008

Journal Articles

Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded Protein Response, Endoplasmic Reticulum Stress and Apoptosis of Human Mantle Cell Lymphoma Cells

Rekha Rao, Warren Fiskus, Yonghua Yang, Rajeshree Joshi, Pravina Fernandez, Pearl Lee, Anand Jillella, Jianguo Tao, Peter Atadja, Eduardo Sotomayor, Kapil N. Bhalla

Blood (2008) 112 (11): 887.

https://doi.org/10.1182/blood.V112.11.887.887

Published: 2008

Journal Articles

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor–resistant acute myeloid leukemia cells

Warren Fiskus, Rekha Rao, Pravina Fernandez, Bryan Herger, Yonghua Yang, Jianguang Chen, Ravindra Kolhe, Aditya Mandawat, Yongchao Wang, Rajeshree Joshi, Kelly Eaton, Pearl Lee, Peter Atadja, Stephen Peiper, Kapil Bhalla

Blood (2008) 112 (7): 2896–2905.

https://doi.org/10.1182/blood-2007-10-116319

Published: 2008

NARROW

Heat Shock Factor 1 Promotes NF-Kb and B-Cell Signaling in a Preclinical Model of Chronic Lymphocytic Leukemia

Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells

Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists

Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells

Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1

Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists

Efficacy of Combined Epigenetic Targeting of Histone Methyltransferase EZH2 and Histone deacetylases Against Human Mantle Cell Lymphoma Cells

Synergistic Activity of Combinations of JAK2 Kinase Inhibitor with PI3K/mTOR, MEK or PIM Kinase Inhibitor Against Human Myeloproliferative Neoplasm Cells Expressing JAK2V617F

Treatment with Histone Deacetylase 6-Specific Inhibitor WT-161 Disrupts hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal ER Stress Induced by Proteasome Inhibitor Carfilzomib

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells

Synergistic Activity of Co-Treatment with PIM1 Kinase Inhibitor SGI-1776 and Histone Deacetylase Inhibitor Panobinostat or Heat Shock Protein 90 Inhibitor AUY922 against Human CML and Myeloproliferative Neoplasm (MPN) Cells.

Targeting Levels, Aberrant Localization or Oligomerization of Mutant Nucleophosmin Induces Differentiation and Loss of Survival of Human AML Cells with Mutant NPM1.

Down-Regulation of Microrna 223 and 148a Mediates Resistance of Human Acute Myeloid Leukemia Cells to Pan-Histone Deacetylase (HDAC) Inhibitors.

Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells

Cotreatment with BCL-2 antagonist sensitizes cutaneous T-cell lymphoma to lethal action of HDAC7-Nur77–based mechanism

Combined Epigenetic Therapy with the Novel Histone Methyl Transferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat Exerts Synergistic Activity against Human Mantle Cell Lymphoma Cells

Anti-AML Activity of Combined Epigenetic Therapy with Novel DNMT1 Inhibitors SGI-110 or SGI-1036 and Histone Deacetylase Inhibitor Panobinostat.

Synergistic Pre-Clinical Activity of Combined Epigenetic Therapy with the Novel Histone Methyltransferase EZH2 Inhibitor 3-Deazaneplanocin and Histone Deacetylase Inhibitor Panobinostat against Human AML Cells.

Co-Treatment with Panobinostat Enhances Bortezomib-Induced Unfolded Protein Response, Endoplasmic Reticulum Stress and Apoptosis of Human Mantle Cell Lymphoma Cells

Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor–resistant acute myeloid leukemia cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only